WINDTREE THERAPEUTICS INC /DE/ Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price
WINDTREE THERAPEUTICS INC /DE/ (WINT) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price of $70174.00 per share for the 9-month period ending 2025-09-30, per its 10-Q filed 2025-11-19.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice · last filed 2025-11-19
- WINDTREE THERAPEUTICS INC /DE/ share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for the quarter ending 2025-03-31 was $58374.86.
- WINDTREE THERAPEUTICS INC /DE/ share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for the quarter ending 2024-03-31 was $0.00, a 100.00% decline year-over-year.
- WINDTREE THERAPEUTICS INC /DE/ share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for the quarter ending 2023-03-31 was $319.69, a 5175.41% increase year-over-year.
- WINDTREE THERAPEUTICS INC /DE/ share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for the quarter ending 2022-03-31 was $6.06, a 48.86% decline year-over-year.
- WINDTREE THERAPEUTICS INC /DE/ share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for fiscal 2024 was $94208.28, a 36271.04% increase from fiscal 2023.
- WINDTREE THERAPEUTICS INC /DE/ share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for fiscal 2023 was $259.02, a 53.03% decline from fiscal 2022.
- WINDTREE THERAPEUTICS INC /DE/ share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for fiscal 2022 was $551.50, a 1559.64% increase from fiscal 2021.
- WINDTREE THERAPEUTICS INC /DE/ share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for fiscal 2021 was $33.23, a 154.44% increase from fiscal 2020.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2025-09-30 | $70174.00 10-Q · filed 2025-11-19 | |||
| 2025-06-30 | $58374.86 10-Q · filed 2025-08-19 | |||
| 2025-03-31 | $58374.86 10-Q · filed 2025-05-15 | |||
| 2024-12-31 | $94208.28 10-K · filed 2025-04-15 | |||
| 2024-09-30 | $2044.85 10-Q · filed 2024-11-26 | |||
| 2024-06-30 | $7214.10 10-Q · filed 2024-08-19 | |||
| 2024-03-31 | $0.00 10-Q · filed 2024-05-15 | |||
| 2023-12-31 | $259.02 10-K · filed 2024-04-16 | |||
| 2023-09-30 | $259.02 10-Q · filed 2023-11-09 | |||
| 2023-06-30 | $299.70 10-Q · filed 2023-08-07 | |||
| 2023-03-31 | $319.69 10-Q · filed 2023-05-15 | |||
| 2022-12-31 | $551.50 10-K · filed 2023-03-31 | |||
| 2022-09-30 | $10.95 10-Q · filed 2022-11-14 | |||
| 2022-06-30 | $9.72 10-Q · filed 2022-08-11 | |||
| 2022-03-31 | $6.06 10-Q · filed 2022-05-05 | |||
| 2021-12-31 | $33.23 10-K · filed 2022-03-31 | |||
| 2021-09-30 | $28.76 10-Q · filed 2021-11-10 | |||
| 2021-06-30 | $17.71 10-Q · filed 2021-08-05 | |||
| 2021-03-31 | $11.85 10-Q · filed 2021-05-13 | |||
| 2020-12-31 | $13.06 10-K · filed 2021-03-29 | |||
| 2020-09-30 | $12.52 10-Q · filed 2020-11-16 | |||
| 2020-06-30 | $38.12 10-Q · filed 2020-08-14 | |||
| 2020-03-31 | $65.17 10-Q · filed 2020-05-13 | |||
| 2019-12-31 | $13.58 10-K · filed 2020-04-03 | |||
| 2019-09-30 | $467.57 10-Q · filed 2019-11-14 | |||
| 2019-06-30 | $463.03 10-Q · filed 2019-08-14 | |||
| 2019-03-31 | $576.33 10-Q · filed 2019-05-20 | |||
| 2018-12-31 | $617.75 10-K/A · filed 2019-04-23 | |||
| 2018-09-30 | $729.80 10-Q · filed 2018-11-14 | |||
| 2018-06-30 | $693.45 10-Q · filed 2018-08-14 | |||
| 2018-03-31 | $369.38 10-Q · filed 2018-05-21 | |||
| 2017-12-31 | $281.80 10-K · filed 2018-04-17 | |||
| 2017-09-30 | $9.43 10-Q · filed 2017-11-14 | |||
| 2017-06-30 | $33.52 10-Q · filed 2017-08-21 | |||
| 2017-03-31 | $112.42 10-Q · filed 2017-05-15 | |||
| 2016-12-31 | $77.14 10-K · filed 2017-03-31 | |||
| 2016-09-30 | $69.15 10-Q · filed 2016-11-14 | |||
| 2016-06-30 | $77.84 10-Q · filed 2016-08-10 | |||
| 2015-12-31 | $42.81 10-K · filed 2016-03-29 | |||
| 2014-12-31 | $15.57 10-K · filed 2015-03-16 | |||
| 2013-12-31 | $28.09 10-K · filed 2014-03-17 | |||
| 2012-12-31 | $24.39 10-K · filed 2014-03-17 | |||
| 2011-12-31 | $44.95 10-K · filed 2014-03-17 | |||
| 2010-12-31 | $51.93 10-K · filed 2013-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VivoSim Labs, INC. (VIVS) | United States | $0.003B | |
| Calidi Biotherapeutics, Inc. (CLDI) | United States | $0.003B | |
| PharmaCyte Biotech, Inc. (PMCB) | United States | $0.005B | |
| CURIS INC (CRIS) | United States | $0.002B | -0.05 |
| Silexion Therapeutics Corp (SLXN) | $0.001B | ||
| AIM ImmunoTech Inc. (AIM) | United States | $0.006B | |
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) | United States | $0.006B | |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |